‘Deployed advanced complex medicine and innovative biotherapeutics platforms’

“Aiming at the development of safer and more effective biotherapeutics, Development Center for Biotechnology (DCB) explored innovative technological platforms for Best-in-Class drug products, including (i) The sitespecific antibody-drug conjugate (ADC) platform developed by DCB for increased efficacy and lower adverse effects; (ii) The Globo H-directed well therapy using a novel CAR-T therapy coupled with immune checkpoint inhibitor PD-L1 antibodies demonstrated a 60 per cent effectiveness on solid tumor inhibition. In addition, allogenic induced pluripotent stem cells (iPSc) has also been generated. (III) The high yield CHO-C cell production system for biotherapeutic proteins was established & well recognised by an award from the 1st Taiwan ResearchInstitute Entrepreneur Ecosystem Programme (TREE); & (iv) The specific FLT3 inhibitor for acute myeloid leukemia (AML) patients drawn international attentions and showing promise in the AML market. Moreover, PROTAC platform and leads for Ras-PROTAC have also shown great & promising results”.

- DR TSAI-KUN LI

Vice President, Development Center for Biotechnology, Taiwan